Potassium iodide ammoniated mixture
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Randomised trials: 3 · 1968–2026
Showing the 50 most relevant studies, sorted by most relevant.
K. Raphael, T. Isakova, Joachim H. Ix, et al.
Journal of the American Society of Nephrology : JASN, 2019
J. Kendrick, Zhiying You, E. Andrews, et al.
Journal of the American Society of Nephrology, 2023
D. Bovée, L. Roksnoer, C. van Kooten, et al.
Journal of Nephrology, 2020
K. Raphael, David J Carroll, J. Murray, et al.
Journal of the American Society of Nephrology : JASN, 2017
Rojesh Timalsina, Surendra Acharya, Bojan Đurin, et al.
Water, 2025
Lakes are vital freshwater ecosystems that sustain biodiversity, support livelihoods, and drive socio-economic growth globally. However, they face escalating threats from anthropogenic activities, including urbanization, agricultural runoff, and pollution, which are exacerbated by climate change. Phewa Lake in Nepal was selected for this study due to its increasing rates of nutrient enrichment, sedimentation, and pollution. This study evaluated seasonal and spatial water quality variations within the lake by analyzing water samples from 30 sites during the pre-monsoon and post-monsoon seasons. Twenty physicochemical parameters, including the potential of hydrogen (pH), dissolved oxygen (DO), electrical conductivity (EC), and major ions, e.g., calcium (Ca2+), magnesium (Mg2+), sodium (Na+), potassium (K+), bicarbonate (HCO3−), chloride (Cl−), sulfate (SO42−), nitrate (NO3−), phosphate (PO43−), and ammonium (NH4+), were measured. The average pH ranged from 8.06 (pre-monsoon) to 8.24 (post-monsoon), reflecting dilution from monsoon rains and increased carbonate runoff. Furthermore, the DO levels in Phewa Lake averaged 7.46 mg/L (pre-monsoon) and 8.62 mg/L (post-monsoon), with higher values observed post-monsoon due to rainfall-driven oxygenation. Nutrient concentrations were shown to be elevated, with the nitrate concentration reaching 2.31 mg/L during the pre-monsoon period, and the phosphate concentration peaking at 0.15 mg/L in the post-monsoon period, particularly near agricultural runoff zones. The dominant cations in the lake’s hydrochemistry were Ca2+ and Mg2+, while HCO3− was the primary anion, reflecting the influence of carbonate weathering. Cluster analysis identified the lake outlet as a high-pollution zone, with the total dissolved solids (TDS) reaching 108–135 mg/L. Additionally, Principal component analysis revealed agricultural runoff and sewage effluents as the main pollution sources. Seasonal dynamics highlighted monsoon-induced dilution and pre-monsoon pollution peaks. These findings underscore the need for targeted pollution control and eutrophication management. By aligning with the sustainable development goals (SDGs) relevant to clean water and climate action, this research provides a replicable framework for sustainable lake management that is applicable to freshwater ecosystems worldwide.
Abstract licence: CC BY
T. Ooi, Y. Uematsu, K. Maruoka
Journal of the American Chemical Society, 2006
Katherine J. Lee, Jacob S. Jordan, Evan R. Williams
Analytical Chemistry, 2024
- Acetates
- Serum Albumin, Bovine
- Protein Stability
Saket Jain, Monojit Batabyal, Raviraj Ananda Thorat, et al.
Chemistry - A European Journal, 2023
Peng X, Zhu J, Lynn HS, et al.
2023
- Cardiovascular Diseases
- Metabolic Syndrome
- Carotenoids
BackgroundThere is limited research on the associations between serum nutritional biomarkers and mortality risk in patients with metabolic syndrome (MetS). Existing studies merely investigated the single-biomarker effect. Thus, this study aimed to investigate the combined effect of nutritional biomarker mixtures and mortality risk using the Bayesian kernel machine regression (BKMR) model in patients with MetS.MethodsWe included the MetS patients, defined according to the 2018 Guideline on the Management of Blood Cholesterol from the National Health and Nutrition Examination Survey (NHANES) 2001-2006. A total of 20 serum nutritional biomarkers were measured and evaluated in this study. The Cox proportional hazard model and restricted cubic spline models were used to evaluate the individual linear and non-linear association of 20 nutritional biomarkers with mortality risk. Bayesian kernel machine regression (BKMR) was used to assess the associations between mixture of nutritional biomarkers and mortality risk.ResultsA total of 1455 MetS patients had a median age of 50 years (range: 20-85). During a median of 17.1-year follow-up, 453 (24.72%) died: 146 (7.20%) caused by CVD and 87 (5.26%) by cancer. Non-linear and linear analyses indicated that, in total, eight individual biomarkers (α-carotene, β-carotene, bicarbonate, lutein/zeaxanthin, lycopene, potassium, protein, and vitamin A) were significantly associated with all-cause mortality (all p-values ConclusionOur findings support the evidence that nutritional status was associated with long-term health outcomes in MetS patients. It is necessary for MetS patients to be concerned with certain nutritional status (i.e., vitamins and mineral elements).
Abstract licence: CC BY
K. Jayanthi, Stacey I. Zones, Alexandra Navrotsky
Crystal Growth & Design, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Structured knowledge from the free knowledge base
Molecular structure

Linked open data from Wikidata (Q121874), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. Molecular structure images from Wikimedia Commons.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.